-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 6, Puli Pharmaceuticals issued an announcement stating that it had recently received a notice of approval of Azithromycin for injection from the New Zealand Drug Administration.
Indications: Suitable for the following infections caused by sensitive pathogens
1.
Patients who are caused by pathogenic bacteria such as Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae, and whose initial treatment requires intravenous administration.
2.
Patients who are caused by Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis and who require intravenous administration for the initial treatment.
Combination therapy.